ICON PLC
ICLR Healthcare Diagnostics & Research
ICON PLC’s revenue for fiscal 2025 (year ended December 2025) was $8.3 billion, up 0.76% from fiscal 2024. In the quarter to June 2026, revenue grew 1.20%, EPS fell 59.3%, free cash flow grew 109.7% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years.
Follow ICLR
ICON PLC (ICLR) P/E ratio
As of 16 October 2026, ICON PLC (ICLR) trades at a P/E ratio of 254×. Over the past ten years it has ranged from 14.7× (May 2016) to 269× (July 2026); the current reading is higher than 99% of that period. That is above the Diagnostics & Research industry median of 35.6× and above the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 70.6× | 202.02% |
| FY2024 | 23.4× | (37.86%) |
| FY2023 | 37.6× | 20.36% |
| FY2022 | 31.3× | (69.60%) |
| FY2021 | 103× | 227.17% |
| FY2020 | 31.4× | 25.08% |
| FY2019 | 25.1× | 15.98% |
| FY2018 | 21.7× | (1.72%) |
| FY2017 | 22.1× | 42.01% |
| FY2016 | 15.5× | (18.24%) |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 260× | 378.25% |
| Mar 2026 | 54.3× | (23.19%) |
| Dec 2025 | 70.6× | 173.93% |
| Sep 2025 | 25.8× | 61.98% |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| TWST Twist Bioscience Corporation compare | n/m |
| GH Guardant Health, Inc. compare | n/m |
| CRL Charles River Laboratories International, Inc. compare | n/m |
| QGEN QIAGEN N.V. compare | 23.6× |
| DGX Quest Diagnostics Incorporated compare | 24.6× |
| LH Labcorp Holdings Inc. compare | 26.2× |
| MEDP Medpace Holdings, Inc. compare | 35.6× |
| RVTY Revvity Inc. compare | 72.7× |
| ICLR ICON PLC | 254× |
| Diagnostics & Research industry median | 35.6× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)